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a  b  s  t  r  a  c  t
Aim:  To  investigate  the plasma  concentrations  of  homocysteine  (Hcy)  in slow  coronary  ﬂow  (SCF)  patients
before and  at the  end  of the  exercise  test  and  compare  with  the  values  of  healthy  controls.
Methods:  Study  population  consisted  of  41  patients  with  SCF  [68%  men,  aged  49  ±  8 years],  and  41  subjects
with  normal  epicardial  coronary  arteries  [56%  men,  aged  50  ±  9  years].  Exercise  test was  performed  in
all study  participants.  Blood  samples  were  drawn  at rest  and  immediately  at the  end  of  exercise  testing
after  12  h of  overnight  fasting.
Results: The  baseline  Hcy  value  of the SCF  patients  was  higher  than  that  of the control  subjects  (p <  0.0001),
and  this  difference  continued  after  exercise  test  between  the  groups  (p  < 0.0001).  Median  post-exercise
increases  in Hcy  levels  were  higher  in the  SCF  group  than  in  the  control  group,  without  a signiﬁcant
difference  (p  =  0.088).  In  the  SCF  group  after  exercise,  Hcy  levels  in  17  patients  with  angina  and  18 patientsT depression with ST  depression  were  higher  than  those  without  angina  and  ST depression  (p < 0.0001  and  p <  0.0001,
respectively).  In addition,  Hcy values  in patients  with  both  angina  and ST depression  were  greater  than
those  with  either  angina  (p  <  0.05)  or ST depression  (p <  0.05).
Conclusion:  The  results  of  this  study  show  that  there  is  an  important  pathophysiologic  link between  the
increased  levels  of  plasma  Hcy,  the degree  of  ischemic  ﬁndings,  and  the  severity  of slow  ﬂow  in  SCF
patients.
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Slow coronary ﬂow (SCF) is an angiographic ﬁnding character-
zed by the slow movement of contrast throughout the coronary
umen in the absence of epicardial coronary obstructive disease.
ince its ﬁrst description, although a number of factors such as
ndothelial, vasomotor, and microvascular dysfunction, and dif-
use coronary atherosclerosis and increased platelet activity have
een responsible for SCF [1–8], its etiopathogenesis is still not fully
lucidated.
Homocysteine (Hcy) is a sulfhydryl-containing amino acid that
ight give rise to endothelial damage and generate free radicals
hat induce oxidative damage and stress. Hyperhomocysteinemia
as been determined as emerging independent risk factor for car-
iovascular system and related diseases [9–12].
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In this study, we  aimed to assess the plasma Hcy levels of SCF
patients before and after very short time exercise, and compared
with those of controls. As far as we know, there is no study investi-




Among 2397 coronary angiograms performed between
February 2011 and March 2012 at cardiology clinics of Lok-
man  Hekim Hospital and Mersin University by reason of suspected
coronary artery disease, 217 (9.1%) had normal epicardial coronary
arteries, i.e. showing no evidence of any coronary stenosis, spasm,
and ectasia. Physical examination and medical history were
assessed. Echocardiographic and electrocardiographic analyses
were performed on all 217 patients. Patients with valvular heart
and/or myocardial disease, systolic and/or diastolic dysfunction,
left ventricular hypertrophy and enlargement detected by the
echocardiographic data were excluded from the study. Patients
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ho suffered from one of the following diseases or related disor-
ers were also excluded: those with a history of acute coronary
yndrome, acute myocardial infarction, percutaneous coronary
ntervention, and coronary artery bypass graft surgery, arrhythmia,
enal dysfunction, connective tissue disease, thyroid disorders,
nd other systemic diseases, and those contraindicated for exer-
ise testing. SCF was determined in 41 of the 217 patients. The
ontrol group, consisting of 41 subjects matched for demographic
haracteristics, was selected in a consecutive manner from the
atheterized patients without exclusion criteria during the same
tudy period. All control subjects, who were proved to have normal
picardial coronary arteries without SCF, had normal exercise and
chocardiographic parameters. After signed informed consent was
btained, all concomitant medications, which may  affect both
esults of the exercise test and Hcy levels such as beta blockers
nd lipid-lowering drugs, were discontinued for at least 30 days
efore the test. The trial was performed according to the principles
f the Declaration of Helsinki and approved by the Investigational
eview Board of Mersin University, School of Medicine.
hrombolysis in myocardial infarction frame count
Coronary ﬂow rates of the all subjects were determined by the
hrombolysis in myocardial infarction (TIMI) frame count (TFC)
ethod. The coronary TFCs were calculated separately for each
ajor coronary artery and their average was determined as the
ean TFC for each subject according to the method described by
ibson et al. [13]. Due to different durations required for nor-
al  visualization of coronary arteries, the corrected cut-off values
ere 36.2 ± 2.6 frames for left anterior descending coronary artery,
2.2 ± 4.1 frames for left circumﬂex artery, and 20.4 ± 3 frames for
ight coronary artery, as has been reported in the literature. The
ubjects with a TFC greater than 2 standard deviations (SD) from
hese thresholds for the particular vessel were accepted as hav-
ng SCF in the present study. All TFCs were measured in matched
rojections using Siemens Medical Solution (version Artis zee,
rlangen, Germany).
xercise treadmill testing
The 12-leads maximal exercise test was carried out using
tandard graduated treadmill protocols consistent with American
eart Association (AHA) guidelines [14]. Patients were encour-
ged to give their maximal effort, but not to allow their angina to
each levels higher than previously experienced. The results were
nalyzed and reported using a computerized database (EXTRA;
osby Publishers; Chicago, IL, USA) [15]. The ST segment response
onsidered was the most horizontal or downsloping ST-segment
epression in any lead, except aVR, during exercise or recovery.
n abnormal response was deﬁned as ≥0.1 mV at 0.08 s after the
 point of horizontal or downsloping ST-segment depression and
ngina (pain felt as pressure, heaviness, and squeezing across the
hest) during exercise or recovery.
aboratory analysis
All blood samples were drawn after 12 h of overnight fas-
ing for total cholesterol (TC), triglyceride (TG), high-density
ipoprotein–cholesterol (HDL-C), complete blood count (CBC), and
reatinine. Assays for TC, TG, HDL-C, and creatinine were per-
ormed using a Cobas Integra 800 automated analyzer (Roche
iagnostics, Mannheim, Germany). Assays for CBC were car-
ied out using a Coulter LH 750 analyzer (Beckman Coulter,
alway, Ireland). The serum low-density lipoprotein–cholesterol
LDL-C) was calculated according to Friedewald’s formula [16].
he glomerular ﬁltration rate (GFR) was estimated as aiology 61 (2013) 138–143 139
function of age, serum creatinine, and race using the simpli-
ﬁed Modiﬁed Diet in Renal Disease (MDRD) equation [eGFR
(mL/min/1.73 m2) = 186.3 × creatinine−1.154 × age−0.203 × (0.742 if
female)] [17].
Analysis of homocysteine levels
Blood samples for Hcy were drawn from the forearm vein at rest
and immediately after the end of exercise testing. After centrifuga-
tion, the obtained plasma was  stored at −20 ◦C. Plasma Hcy levels
were determined by using reagent kit for high-performance liquid
chromatography (HPLC) analysis of Hcy in serum/plasma (Chro-
mosystems GmbH, Munich, Germany). Analyses were performed
with isocratic HPLC system with ﬂuorescence detector (HP 1100).
The HPLC condition for Hcy: injection volume: 20 I, ﬂow rate:
1.7 mL/min, room temperature 25 ◦C, wavelength: EX 385, EM,  515.
High plasma Hcy concentrations were accepted as >12 mol/L [11].
Statistical analysis
Continuous variables were expressed as means ± SD. Categorical
variables were expressed as percentage. The distribution of vari-
ables in both groups was  assessed by the Kolmogorow–Smirnov
test. To compare the two  groups according to changes after the
exercise in the variables that exhibit normal distribution and
according to measurements before and after exercise, independent
t-test was used. In contrast, for the variables that do not show
normal distribution, Mann–Whitney U test was  used. Also in the
patients according to these measurements for comparison of that
with angina and no angina; and also for comparison of those with
ST segment depression and without ST depression, independent
t-test was  used. Paired t-test was used to determine the signiﬁ-
cance of changes observed before and after exercise in both patients
and controls. ANOVA was  used to compare more than two groups.
Post hoc Tukey test was used when the ANOVA found a signiﬁ-
cant effect. Pearson and Sperman correlation analyses were used
for the assessment of relation between variables in both groups. All
hypothesis testing was 2-tailed. p-Values of <0.05 were regarded as
signiﬁcant. Statistical analysis was  performed using SPSS software
package (Version 15.0, SPSS Inc, Chicago, IL, USA).
Results
The clinical characteristics, risk factors, CBC, and TFC of both
groups are delineated in Table 1. There were no statistically sig-
niﬁcant differences between the two  groups in terms of clinical
characteristics and risk factors. TFC was signiﬁcantly higher in
patients with SCF than in control subjects. SCF was detected to
affect left anterior descending artery the most (82.9%), followed
by right coronary artery (53.7%) and circumﬂex (51.2%). SCF was
observed to have a tendency to affect two  vessels (43.9%) or one
vessel (34.1%), whereas three-vessel involvement was less com-
mon  (22%) (Table 1). Plasma baseline Hcy levels of patients with
SCF were found to be signiﬁcantly higher than those of control
subjects (14.9 ± 4.0 mol/L vs 6.5 ± 4.8 mol/L; p < 0.0001, respec-
tively) (Table 2). Post-exercise plasma Hcy levels of SCF patients
were also higher (16.4 ± 4.9 mol/L vs 7.1 ± 5.2 mol/L; p < 0.0001).
The highest Hcy level was determined in patients with SCF in all
of 3 coronary arteries both at baseline and post-exercise, when
compared to that of the controls, one-vessel, and two-vessel SCF
patients (Table 2) (ANOVA p < 0.05 vs control, p < 0.05 vs one-vessel
SCF, and p < 0.05 vs two-vessel SCF, respectively). There was no
signiﬁcant difference for Hcy level between the one-vessel and
two-vessels both at baseline and post-exercise in SCF patients
(p > 0.05). Moreover, the number of vessels with slow ﬂow was
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Table 1
Baseline clinical characteristics, risk factors, laboratory ﬁndings, and TIMI frame counts of both groups.
Controls (n = 41) SCF (n = 41) p
Age (year) 50 ± 9 49 ± 8 NS
Female gender, n (%) 18(44%) 13 (32%) NS
Hypercholesterolemia, n (%) 18 (44%) 19 (46%) NS
Total cholesterol (mg/dL) 202 ± 15 203 ± 16 NS
HDL-cholesterol (mg/dL) 44 ± 8 43 ± 9 NS
LDL-cholesterol (mg/dL) 122 ± 16 123 ± 17 NS
Triglyceride (mg/dL) 179 ± 23 183 ± 28 NS
Hypertension, n (%) 16 (39%) 16 (39%) NS
Systolic blood pressure (mmHg) 135± 17 132± 20 NS
Diastolic blood pressure (mmHg) 80 ± 10 82 ± 11 NS
BMI  (kg/m2) 26.1 ± 4.7 27.4 ± 5.4 NS
Cigarette smoking, n (%) 15 (37%) 12 (29%) NS
Diabetes mellitus, n (%) 6 (15%) 5 (12%) NS
Family history, n (%) 7 (17%) 9 (22%) NS
Creatinine (mg/dL) 0.91 ± 0.19 0.87 ± 0.18 NS
eGFR (mL/min/1.73 m2) 83.8 ± 31.9 92.0 ± 30.2 NS
Red  blood cells (millions/mm3) 5.4 ± 0.5 5.6 ± 0.6 NS
White blood cells (103/mm3) 7.8 ± 1.2 8.2 ± 1.3 NS
Platelets (103/mm) 226 ± 53 244 ± 65 NS
Hemoglobin (g/dL) 13.6 ± 1.4 14.1 ± 1.6 NS
Hematocrit (%) 43.8 ± 4.8 44.9 ± 5.3 NS
TIMI  frame count
LAD 27 ± 4 50 ± 12 <0.0001
LCx  24 ± 3 38 ± 13 <0.0001
RCA 22±  3 37± 12 <0.0001
Mean TIMI frame count 24 ± 2 42 ± 7 <0.0001
Distribution of slow ﬂow
LAD, n (%) 34 (82.9%)
LCx,  n (%) 21 (51.2%)
RCA,  n (%) 22 (53.7%)
Number of slow ﬂow arteries
One vessel, n (%) 14 (34.1%)
Two vessels, n (%) 18 (43.9%)
Three  vessels, n (%) 9 (22.0%)
SCF, slow coronary ﬂow; NS, non-signiﬁcant; TIMI, thrombolysis in myocardial infarction; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index;
eGFR,  estimated glomerular ﬁltration rate; LAD, left anterior descending artery; LCx, left circumﬂex artery; RCA, right coronary artery.
Table  2
Pre-exercise and post-exercise plasma homocysteine levels of both groups.
Controls (n = 41) Slow coronary ﬂow (SCF)
1-V (n = 14) 2-V (n = 18) 3-V (n = 9) Total (n = 41)
Homocysteine (mol/L)
Pre-exercise 6.5 ± 4.8 13.1 ± 3.3* 13.9 ± 3.1* 19.4 ± 3.2*,† 14.9 ± 4.0¶ , *
Post-exercise 7.1 ± 5.2 14.9 ± 4.0* 15.0 ± 4.7* 21.4 ± 4.1*,† ,§ 16.4 ± 4.9¶ , * ,§
Median increase () 0.6 ± 2.2 1.9 ± 3.5 1.1 ± 2.5 2.1 ± 2.4 1.5 ± 2.6
1-V, one-vessel involvement; 2-V, two-vessel involvement; 3-V, three-vessel involvement in SCF group.









Sp < 0.05; SCF patients (all subgroups and total) vs controls (ANOVA).
† p < 0.05; SCF patients subgroup 3-V vs 1-V, and vs 2-V (ANOVA).
§ p < 0.05; SCF patients (subgroup 3-V and total) vs pre-exercise (paired t-test).
ositively correlated with both pre- and post-exercise plasma lev-
ls of Hcy in the SCF group (r = 0.489, p < 0.01; r = 0.419, p < 0.01,
espectively). Median post-exercise increases (Hcy) in plasma
cy level in the SCF group tended to be higher than those of
he control group (Hcy: 1.5 ± 2.6 mol/L vs 0.6 ± 2.2 mol/L;
able 3
xercise parameters of both groups.
Controls
Baseline heart rate (beats/min) 75 ± 8
Peak  exercise heart rate (beats/min) 177 ± 8
Peak  systolic blood pressure (mmHg) 188 ± 11
Rate–pressure product [(mmHg × beats/min)] × 102 332 ± 21
Only  angina, n (%) –
Only  ST depression, n (%) –
Both  angina and ST depression, n (%) –
CF, slow coronary ﬂow.p  = 0.088, respectively) (Table 2), but the result was not statisti-
cally signiﬁcant. Exercise test was  stopped because of only angina
in 5 SCF patients, only ST segment depression in 6 SCF patients,
and both angina and ST depression in 12 SCF patients. Con-
trol subjects completed the whole protocol and none showed
 (n = 41) SCF (n = 41) p-Value
 74 ± 10 NS
 160 ± 13 <0.0001
 178 ± 12 =0.001
 286 ± 30 <0.0001
 5 (12%) –
 6 (15%) –
 12 (29%) –


























Comparison of plasma homocysteine levels at baseline, and after exercise in patients
with and without symptoms in SCF group.
Homocysteine levels (mol/L)
SCF group (n = 41) at baseline 14.9 ± 4.0
SCF group (n = 41) after exercise 16.4 ± 5.0*
(1) No symptoms (n = 18) 11.8 ± 2.5
(2) Only angina (n = 5) 16.9 ± 2.2†
(3) Only ST depression (n = 6) 18.7 ± 2.3† ,§
(4) Both angina and ST depression (n = 12) 22.1 ± 2.2†
SCF, slow coronary ﬂow.
* p = 0.001; SCF group after exercise vs baseline (paired t-test).
† p < 0.05; sub-group 2 vs 1; sub-group 3 vs 1; sub-group 4 vs 1, sub-group 4 vs
2;  sub-group 4 vs 3 (ANOVA).
§ p > 0.05; sub-group 3 vs 2 (ANOVA).ig. 1. Comparison of homocysteine levels at baseline, and after exercise in patients
ith  and without angina in the slow coronary ﬂow group.
T-segment changes, tachyarrhythmias, or angina throughout the
rocedure. Peak exercise heart rate, peak exercise systolic blood
ressure, and rate–pressure product were signiﬁcantly higher in
he control group than in the SCF group. The exercise parame-
ers of the two groups are summarized in Table 3. In the SCF
roup, Hcy values in 17 patients with angina were higher than
hose without angina after exercise (Hcy: 20.6 ± 3.2 mol/L vs
3.5 ± 3.9 mol/L; p < 0.0001, respectively) (Fig. 1). Hcy values
n 18 patients with ST segment depression were also higher
han those without ST segment depression after exercise (Hcy:
0.9 ± 2.7 mol/L vs 12.9 ± 3.2 mol/L; p < 0.0001, respectively)
Fig. 2). In addition, Hcy values in 12 patients with both angina
nd ST depression (22.1 ± 2.2 mol/L) were greater than those
ith only angina (16.9 ± 2.2 mol/L), with only ST depression
18.7 ± 2.3 mol/L), and with no symptoms (11.8 ± 2.5 mol/L)
ANOVA, p < 0.05; p < 0.05; p < 0.05, respectively) (Table 4). Post-
xercise Hcy levels were negatively correlated with the exercise
ate–pressure product among exercise testing parameters in SCF
atients group (r = −0.334, p = 0.03). The mean TFC was positively
orrelated with pre- and post-exercise Hcy concentrations in the
ig. 2. Comparison of homocysteine levels at baseline, and after exercise in patients
ith and without ST depression in the slow coronary ﬂow group.Fig. 3. Correlations between homocysteine levels and mean TIMI frame count pre-
and  post-exercise in the slow coronary ﬂow group. TIMI, thrombolysis in myocardial
infarction.
SCF group (Fig. 3), whereas the mean TFC was  not correlated with
pre- and post-exercise Hcy concentrations in the control group
(p = 0.38, p = 0.21; respectively).
Discussion
The main ﬁndings of our study were the increased level of Hcy
in patients with SCF compared with control subjects at baseline,
and the elevated level of Hcy in patients with angina and ST seg-
ment depression compared to those without angina and ST segment
depression in the SCF group after exercise testing.
Hcy is a potentially cytotoxic amino acid that is synthesized dur-
ing methionine metabolism. Several studies have identiﬁed that
even mild hyperhomocysteinemia is associated with an increased
risk of cardiovascular, and related vascular diseases, indepen-
dently of classic risk factors [9–12]. The main detrimental effects
of Hcy are probably on vascular endothelium. The proposed mech-
anism by which endothelium is damaged by Hcy is impairment
of the basal production of nitric-oxide (NO) in consequence of
the emergence of some biochemically active products such as
hydrogen peroxide (H2O2), superoxide anion (O2−) and hydroxyl
radical (HO) [9,10,18–20]. In humans, reports demonstrated that
elevated Hcy level was associated with impaired endothelium-
dependent vasodilation and suggested that the bioavailability of
NO was decreased in hyperhomocyst(e)inemic persons [18]. In
non-human primates, data showed that a continuous Hcy infusion
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ortic surface, and moderately elevated Hcy induced by methionine
oading resulted in abnormal arterial vasomotor activity [19,20].
ll these human and non-human studies support a strong cor-
elation between the increased plasma Hcy level and endothelial
ysfunction. SCF is an angiographic ﬁnding associated with the slow
ye progression throughout the coronary lumen in the absence
f occlusive coronary artery disease. Some biopsy studies have
hown that SCF is associated with microvascular pathology, includ-
ng myointimal proliferation, medial hypertrophy, reduced luminal
ize, and endothelial degeneration [2,3]. Additionally, a few stud-
es have demonstrated that SCF is not only a microvascular disease,
ut also, may  be a marker of early stage of macrovascular disease
r atherosclerosis [5,6]. Recently, Camsari et al. [6] reported a study
n which patients with SCF had coronary intimal thickness and
arotid intima-media thickness measured, and they concluded that
CF resulted from coronary atherosclerosis. To date, a few studies
21,22] have shown that SCF patients had elevated plasma levels
f Hcy compared to control subjects, supporting the results of our
tudy. Similar to previous trials, our ﬁndings revealed that mean
FC was signiﬁcantly positively correlated with the plasma level
f Hcy in SCF patients. Hence, all this evidence supports the possi-
ility that impaired homocysteine metabolism in SCF patients has
otentially toxic effects on endothelial barrier, as described above,
ulminating in micro- and/or macrovascular disease.
One of the ﬁndings of the current trial was that Hcy levels in
CF patients tend to be greater than those of control subjects after
xercise test, but without a statistical signiﬁcance. To the best of our
nowledge, there is no report on homocysteine values in response
o exercise in patients with SCF. The vast majority of current data
re usually pertained to those of persons who are healthy and/or
bese [23–25]. The data available in the literature demonstrate
hat different exercise protocols may  cause considerable changes
n plasma levels of Hcy. In the present study, a maximal exercise
est that can be easily applied and found in almost all clinics was
erformed using standard graduated treadmill protocols in accor-
ance with AHA guidelines. Acute exercise may  lead to certain
hanges in plasma volume and content, including an increase in
uid osmolarity, circulating adiponectin, and/or arterial pressure,
esulting in ﬁltration of blood ﬂuid into the interstitial area [26,27].
hus, a decrease in plasma volume may  cause hemoconcentration.
lthough the precise mechanism for these increases observed in
ur study remains unclear, hemoconcentration, which may  be fur-
her aggravated owing to the underlying pathophysiology, may
ave contributed to slightly increased Hcy level in SCF patients
ompared to controls.
Another important point of the present study was that plasma
evels of Hcy increased in parallel with the amount of ischemic ﬁnd-
ngs observed after exercise test in the SCF group. Exercise may
how both direct vasoconstrictor and vasodilator effects through -
nd -receptor stimulation, respectively [28]. Increased adrenergic
timulation may  cause abnormal microvascular constriction and
romote coronary ﬂow indirectly through the metabolic vasodi-
ation secondary to an elevation in heart rate and myocardial
ontractility and, in part, to endothelium-mediated vasodilation
28,29]. The net effect is intimately related to the underlying
athophysiologic state of the small coronary arteries. The formerly
ublished reports exhibited that SCF patients were associated with
mpaired endothelium-mediated vasodilation, indicating endothe-
ial dysfunction. Thus, the endothelial dysfunction and increased
ympathetic activation during exercise in SCF patients may  lead
o elevated coronary resistance [30] and, as a result, may  create
 suitable territory for the myocardial ischemia in pre- and espe-
ially post-exercise period. Indeed, Yazici et al. [31] showed higher
drenaline and noradrenaline levels both at baseline and after exer-
ise, and a signiﬁcant correlation between TFC and ischemia in SCF
atients, indicating that elevated adrenergic activity could be theiology 61 (2013) 138–143
manifestation of SCF. Moreover, Turkmen et al. [7] reported that
SCF phenomenon may  alone lead to myocardial ischemia even in
the absence of obstructed major epicardial coronary arteries as
detected by similar exercise QRS scores to those of signiﬁcant coro-
nary artery stenosis, a ﬁnding supporting the results of the current
trial, and they concluded that microvascular disorders and vasomo-
tor changes frequently observed in this group of patients could be
the responsible mechanisms. Oudi et al. [32] have demonstrated
that elevated levels of Hcy are associated with a greater number
of diseased arteries and, consequently, the severity of coronary
artery disease. In addition, Ankrah et al. [12] showed that there
was a correlation between plasma Hcy level and the presence of
myocardial perfusion defects in patients with coronary artery dis-
ease, especially those with multiple risk factors and multivessel
infarction. In keeping with these ﬁndings, we detected that patients
with SCF in all of three vessels had higher plasma levels of Hcy when
compared to the controls and patients with SCF in one and two ves-
sels. Tanriverdi et al. [22] showed that increased concentrations of
Hcy were negatively correlated with endothelial function in SCF
patients. We  also found that post-exercise Hcy levels were nega-
tively correlated with the exercise rate–pressure product among
exercise testing parameters and, the mean TFC was positively cor-
related with post-exercise level of Hcy in the SCF group. Therefore,
it can be concluded that increased levels of plasma Hcy may  be
closely related to the degree of possible endothelial dysfunction,
the severity of slow ﬂow in the affected vessels, and/or the presence
of multivessel involvement that could make SCF patients more sen-
sitive to ischemia during an adrenergic activation such as exercise
through the discussed mechanisms above.
Study limitations
The small number of patients recruited for our study is the main
limitation. Moreover, another limitation is that plasma levels of the
folic acid, vitamin B12 were not able to be measured simultaneously
with the plasma Hcy level to determine the possible disorder of Hcy
metabolism. Hematocrit, ﬁbrinogen, serum total protein or albu-
min, osmolarity, uric acid, and the density and viscosity of blood
and plasma have been used as measures of dehydration and hemo-
concentration. All these parameters were not assessed to detect
whether acute exercise caused hemoconcentration. An inﬂamma-
tory parameter, C-reactive protein, and single-photon emission
computed tomography analysis, and ﬂow-mediated vasodilatation,
a marker of endothelial function, were not investigated. Further
studies with larger samples are needed to conﬁrm our results.
Conclusion
We found that patients with SCF had increased levels of Hcy
pre- and, to a lesser extent, after exercise compared with con-
trol subjects. Our study also demonstrated that SCF patients with
angina and ST segment depression during exercise test had higher
Hcy values than those without angina and ST segment depression.
These ﬁndings might suggest an important pathophysiologic link
between the increased plasma Hcy levels, the number of slow ﬂow
coronary arteries, and exercise-related ischemic ﬁndings in SCF
patients, in particular those with both angina and ST depression.
The present trial is the ﬁrst report to evaluate the relation between
exercise and Hcy plasma levels in this patient group.Conﬂict of interest
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